Status:
COMPLETED
The McGill RAAS-COVID-19 Trial
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Jewish General Hospital (Montreal, Quebec, Canada)
Montreal General Hospital (Montreal, Quebec, Canada)
Conditions:
COVID-19
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronavirus disease (COVID-19) related pneumonia significantly impact patients with underlying cardiovascular (CV) conditions. Animal studies suggest that drugs commonly used to treated CV diseases ma...
Detailed Description
Open-label, pragmatic, randomized, study of approximately 40 adults. The following groups of participants will be considered: i) within 48 hours of diagnosis of COVID-19; ii) who have received a diagn...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old.
- Hospitalization with a Covid-19 infection
- Chronically treated with RAAS blockers (ACE inhibitors or ARBs on the last prescription prior to admission with a treatment duration ≥ 1 month
- Diagnosis of COVID-19 confirmed by the presence of SARS-CoV-2 on any biological sample
- Participants are within 48 hours of diagnosis of COVID-19 or have received a diagnosis of COVID-19 from another facility and are within 48 hours of transfer to a study recruitment site
Exclusion
- Shock requiring vasoactive agents.
- Requiring invasive mechanical ventilation.
- History of malignant hypertension
- Use of five or more antihypertensive drugs.
- History of heart failure with reduced ejection fraction
- History of hospitalization for acute heart failure in past 3 months
- History of hospitalization for hemorrhagic stroke in the past 3 months.
- History of CKD with an eGFR \<45 ml/min/1.73m2
- History of COPD GOLD III/IV
- History of end-stage dementia
- History of active liver cirrhosis
- RAAS blockers therapy previously stopped \> 48h.
- Anticipated discharge in less than 24 hours.
- History of current active cancer receiving chemotherapy
- Inability to obtain informed consent.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 17 2021
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04508985
Start Date
October 1 2020
End Date
April 17 2021
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Muhc-Rimuhc
Montreal, Quebec, Canada, H4A 3J1